美股异动 | 获默沙东92亿美元收购 Cidara Therapeutics(CDTX.US)开盘飙升超105%

Core Viewpoint - Cidara Therapeutics (CDTX.US) shares surged over 105% following Merck's announcement of a $9.2 billion acquisition deal, marking a significant milestone for the company and its innovative long-acting flu antibody products [1] Company Summary - Merck (MRK.US) has reached a definitive agreement to acquire Cidara Therapeutics for $221.50 per share in cash, totaling approximately $9.2 billion [1] - The acquisition has been approved by the boards of both companies but is subject to regulatory approvals, including the Hart-Scott-Rodino Antitrust Improvements Act (HSR) [1] - The transaction is expected to close in the first quarter of 2026, enhancing Merck's respiratory product portfolio and research pipeline [1]